| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33c922e05f6133b7d72dbb849d77487d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 |
| filingDate |
2022-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc33d822a93bb8bccddfaff14e64d7a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da68b76ee7b4f76d930c625b693c39b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2c74a919905ea9cd066756a333c7f3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f6f83b659d14fc1c12c155a88f0e2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_388983a436d685d9e32b34b086f572b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_918793a82cb39555cde10f84b09f0d09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ccebf931b2dbb2f70c71051f8ca3f95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95b2fa7207a4b7e8c2ef19c03ca36ab7 |
| publicationDate |
2022-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022265378-A1 |
| titleOfInvention |
Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
| abstract |
The present invention relates to: a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof; and a method for preventing or treating hyperuricemia-related diseases using same. The pharmaceutical composition according to the present invention can effectively reduce the blood uric acid concentration of a patient with a hyperuricemia-related disease. |
| priorityDate |
2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |